Cardio Diagnostics Holdings (NASDAQ: CDIO), an AI-driven precision cardiovascular medicine company, announced the official launch of its in-house, high-complexity CLIA-certified laboratory in Iowa City, Iowa, giving the company end-to-end control over processing of its multi-omics clinical tests, Epi+Gen CHD(TM) and PrecisionCHD(TM), from sample receipt through result delivery. The facility received its federal Clinical Laboratory Improvement Amendments (“CLIA”) license following an inspection that found no deficiencies and has secured out-of-state licenses from California, Maryland, Rhode Island and Pennsylvania, with New York licensing in progress.
Cardio Diagnostics said bringing processing in-house is expected to provide greater control over costs, quality and turnaround times while improving unit economics as sample volume grows, with the company targeting gross margins of approximately 40% at scale. Current turnaround time is seven to 10 business days from sample receipt. The facility also includes a research laboratory supporting the company’s work in precision epigenetic methods and development of a high-precision cardiovascular health monitoring system.
To view the full press release, visit https://ibn.fm/44Xz1
About Cardio Diagnostics
Cardio Diagnostics is an artificial intelligence-powered precision cardiovascular medicine company that makes cardiovascular disease prevention, detection, and management more accessible, personalized, and precise. The company was formed to further develop and commercialize clinical tests by leveraging a proprietary Artificial Intelligence (AI)-driven Integrated Genetic-Epigenetic Engine (“Core Technology”) for cardiovascular disease to become one of the leading medical technology companies for improving prevention, detection, and treatment of cardiovascular disease.
NOTE TO INVESTORS: The latest news and updates relating to CDIO are available in the company’s newsroom at https://ibn.fm/CDIO
About PsychedelicNewsWire
PsychedelicNewsWire (“PNW”) is a specialized communications platform with a focus on all aspects of psychedelics and the latest developments and advances in the psychedelics sector. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, PNW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, PNW brings its clients unparalleled recognition and brand awareness. PNW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from PsychedelicNewsWire, text “Groovy” to 888-902-4192 (U.S. Mobile Phones Only)
For more information, please visit https://www.PsychedelicNewsWire.com
Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer
PsychedelicNewsWire
Austin, Texas
www.PsychedelicNewsWire.com
512.354.7000 Office
Editor@PsychedelicNewsWire.com
PsychedelicNewsWire is powered by IBN
